Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3

2(66.7%)

N/A

1(33.3%)

3Total

Phase 3(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04549831Recruiting

Genetic Bases of COVID-19 Clinical Variability

Role: collaborator

NCT03049995Unknown

Stress Echo 2020 - The International Stress Echo Study

Role: collaborator

NCT04366921Unknown

European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO

Role: collaborator

NCT04382794Completed

Sitagliptin Treatment in Diabetic COVID-19 Positive Patients

Role: collaborator

NCT01672138Not ApplicableUnknown

Pulmonary Vein Antrum Isolation (PVAI) Plus Scar Homogenization and Non-PV Triggers Ensure Long-term Recurrence-free Survival in Non-paroxysmal Atrial Fibrillation

Role: collaborator

NCT01439386Phase 3Completed

Impact Of Different Ablation Approaches on Outcome In Coexistent Atrial Fibrillation and Flutter

Role: collaborator

NCT01045668Phase 3Completed

Ablation of Clinical Ventricular Tachycardia Versus Addition of Substrate Ablation on the Long Term Success Rate of VT Ablation

Role: collaborator

All 7 trials loaded